Today, the FDA approved a new treatment, Qbrexza cloth, for extreme underarm sweating, aka primary axillary hyperhidrosis, in adults and children ages nine and older. Nearly 10 million Americans suffer from hyperhidrosis.
The prescription topical wipe, which is applied directly to the skin (only the underarm area), works by inhibiting the activation of the sweat glands, therefore limiting the production of sweat. Packaged as single-use pre-moistened cloths, the medicine should be applied every 24 hours to clean, dry, unbroken skin. Immediately after using Qbrexza, it is important to thoroughly wash the hands—if the medicine is still on the hands and the eyes are touched, blurred vision can result.
You May Also Like: Can Armpit Masking Really Fight Excessive Sweating and B.O.?
“For years, dermatologists have been telling us of the need for new treatment options that address primary axillary hyperhidrosis given the stigma and burden associated with this condition,” says Tom Wiggans, chairman and chief executive officer at Dermira. “From the start, our goal was to develop an approach that went beyond masking a person’s excessive underarm sweating, and instead, focused on treating the condition in a clinically meaningful way. It is our hope that Qbrexza will not only provide the clinical benefit these sufferers have been seeking, but als help to reduce the overall burden on their lives.”
Qbrexza will be available by prescription in October 2018.
